NCT06632964View on ClinicalTrials.gov

A Clinical Trial Aimed At Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 18, 2024

Primary Completion Date

September 1, 2025

Study Completion Date

October 1, 2025

Conditions
Non-muscle Invasive Bladder Cancer
Interventions
BIOLOGICAL

Recombinant oncolytic adenovirus injection solution of VT-101

Active ingredient: VT-101 recombinant oncolytic adenovirus Specifications: 2×10\^10 IFU/ml, 0.5ml/ capsule Method of administration: intravesical perfusion

Trial Locations (1)

221000

RECRUITING

Affiliated Hospital of Xuzhou Medical University, Xuzhou

All Listed Sponsors
collaborator

Xuzhou Medical University

OTHER

lead

The Affiliated Hospital of Xuzhou Medical University

OTHER